US farm agency ends program to support small businesses
The cuts are another hit to farmers from President Donald Trump's effort to shrink the size and cost of the federal government. The administration has previously canceled programs for local foods and food banks and climate-friendly farming, among others.
Agriculture Secretary Brooke Rollins said in a statement that the agency was terminating the Regional Food Business Centers program because they were not financially sustainable.
Four of the 12 centers will close immediately, and the remaining eight have the option to continue managing existing grants through next May, Rollins said.
"USDA will honor existing commitments for over 450 grants to farmers and food businesses to ensure planning decisions on the farm can continue as normal, however stakeholders should not plan on this program continuing," she said.
The USDA under former President Joe Biden spent $400 million to open the centers as part of its effort to increase resilience and competition in the U.S. food supply chain. The centers have provided training or technical assistance to more than 5,500 farms and businesses, according to a 2024 progress report.
"The USDA has made yet another decision to prematurely end multi-year agreements that are effectively serving the small family farms the administration claims to be the focus of their agenda," said Hannah Quigley, policy specialist at the National Sustainable Agriculture Coalition, a policy and advocacy group.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
a few seconds ago
- The Independent
Trump's approval rating has dropped to a new low
Donald Trump 's approval rating has fallen to 40 per cent, marking the lowest point of his second presidential term, according to a new Reuters/ Ipsos poll. The poll indicates a sharp national divide, with 83 per cent of Republicans approving, but only three per cent of Democrats and a third of independents supporting his performance. While approval for his handling of the economy and immigration policies saw slight increases, his overall rating has dropped by approximately 12 points since January. Trump's approval among men has significantly declined, with a CBS / YouGov poll showing 47 per cent approval compared to 54 per cent before his second electoral victory. The dip in ratings comes as some of his core supporters question his administration's handling of the 'Epstein files', despite earlier promises of transparency.
Reuters
a minute ago
- Reuters
Exclusive: UN says Congo rebels killed scores of farmers, M23 suggests 'smear'
PARIS, July 31 (Reuters) - An M23 rebel attack on farmers and other civilians in east Democratic Republic of Congo killed 169 people earlier this month, a U.N. body told Reuters, in what would be one of the deadliest incidents since the Rwanda-backed group's resurgence. M23 leader Bertrand Bisimwa told Reuters it would investigate but the report could be a "smear campaign". The U.N. rights body's account has not been previously reported and emerged as U.S. President Donald Trump's administration pushes for peace between Congo and Rwanda that it hopes will unlock billions in mineral investments. Reuters has not been able to independently confirm the killings but a local activist cited witnesses as describing M23 combatants using guns and machetes to kill scores of civilians. The M23 and Congolese government have pledged to work towards peace by August 18 after the rebels this year seized more territory than ever before in fighting that has killed thousands and displaced hundreds of thousands more. According to findings by the U.N. Joint Human Rights Office (UNJHRO), which monitors Congo, the M23 operation that led to the farmers' killings began on July 9 in the Rutshuru territory of North Kivu province. It targeted suspected members of the Democratic Forces for the Liberation of Rwanda (FDLR), a Congo-based group that includes remnants of Rwanda's former army and militias that carried out the 1994 Rwandan genocide, UNJHRO said. 'Civilians, mainly farmers temporarily camping in their fields for the ploughing season, have been attacked. The human toll has been particularly high: at least 169 people have been killed,' UNJHRO said in findings shared by Reuters. The victims were 'far from any immediate support or protection,' UNJHRO said, citing credible information from several independent sources. In response, M23's Bisimwa said the group had been notified about UNJHRO's findings in a letter and would form a commission to investigate the unconfirmed accusations. "We believe that before imposing sanctions, the facts must first be established by verifying their actual existence through an investigation," he said. "This rush to publish unverified information is propaganda whose purpose is known only to the United Nations Joint Human Rights Office," he said, adding that the allegations could be part of a "smear campaign" by Congolese employees of UNJHRO. UNJHRO is made up of the human rights division of Congo's U.N. peacekeeping mission and the former office of the U.N. high commissioner for human rights in Congo. It has both Congolese and foreign staff members. The activist in Rutshuru, who did not want to be named for safety reasons, told Reuters the M23 combatants killed more than 100 civilians, mostly Congolese Hutu farmers. The victims had initially fled when M23 advanced on the territory, but they returned after M23 promised them safety, the activist said. U.N. human rights chief Volker Turk said last month that M23, Congo's army and allied militias had all committed abuses in eastern Congo, many of which may amount to war crimes. Rwanda has long denied helping M23 and says its forces act in self-defence against Congo's army and ethnic Hutu militiamen linked to the 1994 Rwandan genocide, including the FDLR. A report by a group of United Nations experts published this month said Rwanda exercised command and control over M23 and was backing the group in order to conquer territory in east Congo. A government spokesperson said at the time that the report misrepresented Rwanda's security worries related to the FDLR and affiliated groups. The spokesperson, Yolande Makolo, did not respond to a request for comment about UNJHRO's findings. Persistent violence in eastern Congo threatens Trump's vision for the region, which has been plagued by war for decades and is rich in minerals including gold, cobalt, coltan, tungsten and tin. A peace agreement signed on June 27 in Washington by the Congolese and Rwandan foreign ministers requires Congo to "neutralise" the FDLR as Rwanda withdraws from Congolese territory. Both the Congolese operations against the FDLR and the Rwandan withdrawal were supposed to have started on Sunday, though it is unclear what progress has been made. They have three months to conclude. Congolese government spokesperson Patrick Muyaya told Reuters the killings in Rutshuru demonstrate that M23 is a destabilising force incapable of bringing security. Kinshasa wants a peace deal that will allow for the restoration of its authority in the region, Muyaya said.
Reuters
a minute ago
- Reuters
Sanofi raises annual sales growth expectations on strong Dupixent demand
July 31 (Reuters) - France's Sanofi ( opens new tab said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments. It had previously forecast annual sales to grow by mid-to-high single-digit percentage at constant currency rates. The drugmaker confirmed it expects earnings to grow by a low double-digit percentage this year, but said the forecast now includes all expenses from its newly acquired businesses. Sanofi has significantly amped up its R&D expenditure in recent years and plans to be more active with acquisitions as it looks to build its next wave of growth drivers beyond its asthma drug Dupixent. It recently closed its up to $9.5 billion acquisition of Blueprint Medicines, a maker of rare immunology disease treatments. But investor hopes remain high for the anti-inflammatory drug Dupixent, the company's main growth driver, especially since it was approved for a common lung condition called chronic obstructive pulmonary disease last year. Sales of Dupixent, which it makes with partner Regeneron (REGN.O), opens new tab, rose 21.1% to 3.83 billion euros ($4.38 billion), compared to 3.74 billion euros expected on average by analysts in a company-provided poll. Chief Financial Officer François-Xavier Roger said that outside of the U.S., sales of the drug exceeded 1 billion euros. "We are very confident in our sales target of around 22 billion euros in 2030," Roger said about the drug. Quarterly business operating income, excluding one-off items, came in at 2.46 billion euros, below the average analyst estimate of 2.57 billion euros in a poll posted on the company's website. Sanofi said higher research costs and higher profit sharing with its partner Regeneron weighed on its earnings during the quarter. Vaccines sales rose a currency-adjusted 10% to 1.21 billion euros in the quarter, ahead of a 1.14 billion euro analyst consensus. ($1 = 0.8740 euros)
